CardioACC, a Shenzhen-based company specializing in cardiovascular interventional imaging and treatment technologies, has launched a regulatory study for its 7.5F 2D intracardiac ultrasound imaging system (ICE), successfully enrolling dozens of patients. This ultrasound catheter model is smaller than any currently marketed ICE products globally, nearing the industry’s design limits. The innovation aims to reduce complications from puncture injuries while delivering high-quality ICE solutions to patients in China.
In December of last year, CardioACC raised “tens of millions” of renminbi, with the funds allocated for regulatory studies and the development of next-generation products.- Flcube.com
